**Optimising design of research to evaluate antibiotic stewardship interventions; consensus recommendations of a multinational working group.**

Valentijn A. Schweitzer1, Cornelis H. van Werkhoven1, Jesús Rodríguez Baño2, Julia Bielicki3, Stephan Harbarth4, Marlies Hulscher5, Benedikt Huttner6, Jasmin Islam7, Paul Little8, Celine Pulcini9, Alessia Savoldi10,11, Evelina Tacconelli10,11, Jean-Francois Timsit12, Maarten van Smeden13. Martin Wolkewitz14, Marc J.M. Bonten15, A. Sarah Walker16,17, and Martin J. Llewelyn7, Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) Working Group on Design of Antimicrobial Stewardship Evaluations.

*1. Julius Center for Health Sciences and Primary Care, University Medical Centre Utrecht, The Netherlands*

*2. Unit of Infectious Diseases, Clinical Microbiology and Preventive Medicine, Department of Medicine, Hospital Universitario Virgen Macarena, Universidad de Sevilla and Biomedicine Institute of Sevilla (IBiS), Seville, Spain*

*3 Paediatric Infectious Disease Research Group, St George's University of London, London, United Kingdom*

*4. Divisions of Infectious Diseases and Infection Control, Geneva University Hospitals and Faculty of Medicine, Switzerland*

*5. Scientific Center for Quality of Healthcare, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.*

*6. Department of Infectious Diseases and Infection Control, Hôpitaux Universitaires de Genève, Switzerland*

*7. Department of Global Health and Infection, Brighton and Sussex Medical School, Falmer, United Kingdom*

*8. Department of Primary Care Research, University of Southampton, Southampton, United Kingdom*

*9. Infectious Diseases Department, Université de Lorraine, CHRU-Nancy, and APEMAC, Université de Lorraine, Nancy, France.*

*10. Infectious Diseases, Department of Diagnostic and Public Health, Verona, Italy*

*11. University Hospital; Internal Medicine, Tuebingen University, Germany.*

*12. University of Paris, IAME ; Inserm; Medical and Infectious diseases ICU (MI2), Bichat hospital; F75018 , Paris France.*

*13. Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.*

*14. Institute for Medical Biometry and Statistics, University of Freiburg, Germany*

*15. Department of Medical Microbiology, University Medical Center Utrecht, The Netherlands*

*16. MRC Clinical Trials Unit, University College London, London, United Kingdom*

*17. Nuffield Department of Medicine, University of Oxford, United Kingdom*

**Keywords:** antibiotic stewardship, research design

**Running title:** Recommendations for design of antibiotic stewardship research studies

**Corresponding author:**

Martin J Llewelyn

Department of Global Health and Infection

Brighton and Sussex Medical School

University of Sussex

Falmer, East Sussex. BN1 9PS

United Kingdom

m.j.llewelyn@bsms.ac.uk

**Abstract**

**Scope**

Antimicrobial stewardship interventions and programmes aim to ensure effective treatment while minimising antimicrobial-associated harms including resistance. Practice in this vital area is undermined by the poor quality of research addressing both what specific antimicrobial use interventions are effective and how antimicrobial use improvement strategies can be implemented into practice. In 2016 we established a working party to identify the key design features which limit translation of existing research into practice and then to make recommendations for how future studies in this field should be optimally designed. The first part of this work has been published as a systematic review. Here we present the working group’s final recommendations.

**Methods**

An international working group for design of antimicrobial stewardship intervention evaluations was convened in response to the fourth call for leading expert network proposals by the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR). The group comprised clinical and academic specialists in antimicrobial stewardship and clinical trial design from six European countries. Group members completed a structured questionnaire to establish the scope of work and key issues to develop ahead of a first face-to-face meeting which 1) identified the need for a comprehensive systematic review of study designs in the literature and 2) prioritised key areas where research design considerations restrict translation of findings into practice. The working group’s initial outputs were reviewed by independent advisors and additional expertise was sought in specific clinical areas. At a second face-to-face meeting the working group developed a theoretical framework and specific recommendations to support optimal study design. These were finalised by the working group co-ordinators and agreed by all working group members

**Recommendations**

We propose a theoretical framework in which consideration of the **intervention rationale** the **intervention setting, intervention features** and the **intervention aims** inform selection and prioritization of outcome measures, whether the research sets out to determine **superiority** or **non-inferiority** of the intervention measured by its primary outcome(s), the most appropriate **study design** (e.g. experimental or quasi- experimental) and the **detailed design features**. We make eighteen specific recommendation in three domains: outcomes, objectives and study design.

**Conclusions**

Researchers, funders and practitioners will be able to draw on our recommendations to most efficiently evaluate antimicrobial stewardship interventions.

**Background and context**

Antimicrobial resistance is a rapidly growing and major threat to human health (1). Overuse of antimicrobials drives resistance at the individual (2) and population level (3). The term antimicrobial stewardship refers to interventions and programmes which aim to optimise antimicrobial use; achieving effective treatment while minimising antimicrobial-associated harms including resistance (4).

Despite the large and exponentially increasing number of studies published since the term Antimicrobial Stewardship was coined (5-7), evidence remains remarkably weak both for ***what*** specific antimicrobial use interventions are effective (in terms of mortality, length of stay, adverse events, resistance rates) and ***how*** antimicrobial use improvement strategies can be implemented to deliver the desired antimicrobial use in daily clinical practice (8). A 2016 systematic review of evidence supporting key antimicrobial use interventions (e.g. prescribing according to guidelines, de-escalation of therapy, intravenous to oral switching) identified predominantly low-quality and highly heterogenous supporting evidence (9). The evidence around improvement strategies is similarly weak, dominated by uncontrolled before-after studies and inadequately performed interrupted time series analyses, mostly performed within single hospitals (10).

We recently reported a broad systematic review of antimicrobial stewardship intervention studies which highlighted key frequent design weaknesses (7). Studies which aim to assess effectiveness of antimicrobial use interventions are typically under powered and fail to provide evidence on safety or even do not report clinical outcome data at all. Improvement strategy studies are often multifaceted with inadequate process evaluation to allow mediators of impact to be assessed (11). Generally, the field of antimicrobial stewardship research is dominated by single-centre observational and quasi-experimental studies which fail to deal optimally with risks of different forms of bias and that lack external validity (7, 8).

Building on this work we established a working group of investigators in this field which used a consensus-building iterative process over 12 months to build a conceptual framework and develop specific recommendations for the design of stewardship evaluations, which were then reviewed and amended by an expert advisory committee. This guidance is the final result of that process and aims to support investigators when making key design decisions and funders assessing proposals for studies of antimicrobial stewardship interventions and hopefully enhances the quality and impact of research in this crucial area.

**Methods**

An international working group for design of antimicrobial stewardship intervention evaluations was convened in response to the fourth call for leading expert network proposals by the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR). The study sponsor was the UK Medical Research Council. The working group co-ordinators (MJMB, MJL) and co-applicants (VAS, ASW and CHvW) purposively selected an additional eight leading clinical and academic specialists in antimicrobial stewardship and clinical trial design from six European countries (France, Germany, Italy, the Netherlands, Spain, Switzerland and the UK) to contribute. Selection secured input from the diversity of professionals involved in antimicrobial stewardship practice (infection, internal medicine, intensive care medicine) and research (trial design, statistics and qualitative research) disciplines. Consensus was sought through a nominal group process. Group members completed a structured questionnaire to establish the scope of work, key study designs used in antimicrobial stewardship, identify the major limitations on different study designs and key issues to develop ahead of a first face-to-face meeting. The group met in March 2017 and anonymised responses were feedback to the whole group and relevant literature was presented (VAS, CHvW, MJL). This identified the need for a comprehensive systematic review of study designs in the literature. In parallel, in moderated small group work, candidate solutions were proposed to address the limitations identified, and in a final round-table moderated discussion the group prioritised four key areas where research design considerations restrict translation of findings into practice: features of the intervention under evaluation; appropriate selection of outcome measures; demonstration of superiority / non-inferiority of the intervention according to the outcome measures selected and strategies to minimise bias within experimental and quasi-experimental study designs. The working group’s initial outputs were reviewed by two independent advisory experts, both senior, clinically active antimicrobial stewardship experts in different European countries. Their input prompted widening the group to bring in additional expertise in the field of implementation research, primary care and paediatrics. A second face-to-face meeting the working group used the findings of the systematic review to develop a theoretical framework through which researchers can address these four key research design considerations. The group proposed a series of key questions researchers can use to highlight the major issues they need to address to arrive at an optimal design for their specific research project. Final agreement of recommendations presented here by all eighteen members of the working group was achieved by email.

**A THEORETICAL FRAMEWORK FOR DESIGNING ANTIMICROBIAL STEWARDSHIP EVALUATIONS**

**The impact of intervention design**

Detailed discussion of how antimicrobial stewardship interventions are designed is beyond the scope of this guidance. However, the design of the scientific evaluation of an intervention depends on how that intervention was designed, and this then may depend on a set of interdependent considerations (Figure 1a). The **intervention rationale** should include its basis in theory and existing evidence. (Table 1 is a glossary of terms used in this guidance). The existing evidence that informed the research question should be clearly explained on an efficacy-effectiveness-implementation spectrum (12), as these considerations will determine how outcomes are selected and prioritized (Figure 1b). Detailed characterization of the **intervention setting** is required to allow assessment of external validity and to minimize selection bias. Stewardship interventions are typically multifaceted and each **intervention feature** must be specified precisely. The same holds for how the intervention’s impact will be determined; this will influence definition and selection of outcomes, selection of clusters/sites and feasibility of blinding. The **intervention aims** will be informed by the rationale and setting and will also be key to selecting the **primary** and **secondary** **outcomes;** whether these will determine effectiveness and safety or how implementation results change antimicrobial use and what data are required to support translation of study findings into practice. These considerations will inform whether the research sets out to determine **superiority** or **non-inferiority** of the intervention measured by its primary outcome(s) against standard practice and the detectable effect sizes/non-inferiority margins, the most appropriate **study design** (e.g. experimental or quasi- experimental) and the **detailed design features**.

**Recommendations regarding selection of outcome measures**

When assessing the impact of a stewardship intervention, researchers should aim to consider all intended and potential unintended effects (13-15). Outcome measures can be helpfully grouped into three domains as clinical (typically to assess safety of an antimicrobial-sparing intervention in terms of patient outcome), microbiological (resistance), and care-related (processes and structures of care, sometimes referred to as quality or performance outcomes) (16) (table 2). Whether the study is primarily assessing effectiveness, implementation or a combination of both, will determine how outcomes are selected and prioritised, but, in general, appropriate outcome measures should be prospectively defined from each of the three domains. It is essential to recognise that whilst individually randomised efficacy trials aim to avoid selection bias, the inevitably restricted populations that enter such trials can potentially lead to generalisability bias, making extrapolation to wider populations challenging. While stewardship studies typically assess interventions made at the cluster level, assessment of clinical, microbiological and care related outcomes is often possible at an individual patient level and should be included where possible to address this.

***Clinical outcomes*** are missing from many published stewardship studies. In fact, most of these studies were not sufficiently powered to exclude clinically meaningful harm. Concern that this prevents adoption of antimicrobial reduction strategies into practice has led some to call for routine use of co-primary clinical outcomes in stewardship evaluations (17). The working group felt that clinical outcome measures should always be pre-specified and reported. Exceptions could be implementation studies of interventions for which concerns over safety will not be a barrier to adoption of their findings.

***Microbiological outcomes*** address the impact of the intervention on antimicrobial resistance and/or rates of *Clostridium difficile* infection. A central rationale for antimicrobial stewardship interventions is that reducing antimicrobial exposure should reduce harm to a patient’s microbiome and selection for antibiotic resistance. However, the evidence base remains sparse, and mostly of low quality, with lack of reliable pre-intervention data a particular limitation (9, 18, 19). Incorporating assessment of colonisation/infection by resistant organisms within a stewardship study can be challenging as event rates are often low and the relationship between antimicrobial exposure and resistance may be temporally distant and complicated by interactions with exposure to resistant pathogens and infection control measures. The working group agreed that while reductions in antimicrobial resistance should not be the primary outcome of stewardship studies, measurement of prevalence or incidence of *C. difficile* infection and of antimicrobial resistance should be included in the design where possible, and it should be clear whether measured resistance is in relation to the infecting pathogen and type of infection or among colonising strains.

***Care provision outcome measures*** (sometimes called quality or performance measures)include process indicators, prescribing behaviours, and antimicrobial use data. These are usually relatively straightforward to obtain and are important to gather and report since clinical outcomes can only be interpreted meaningfully if it is clear that patient management has truly changed. Process indicators may address prescribing quality (e.g. guideline adherence or documentation practice) and reveal mediators of observed results. They are particularly important in implementation research to assess how the intervention under evaluation was actually delivered across the study (fidelity). This allows distinction between strategies that do and do not change the behaviours they aim to change and identification of those elements of an intervention that are impactful and of barriers for implementation (11). Gathering appropriate qualitative data (e.g. from service managers, care providers and patients as appropriate) will allow an intervention’s impact on cultural aspects of antibiotic use to be evaluated. Process outcomes are needed to assess organisational impact, of both implementation and long-term sustainability. Sustainability assessment is particularly important when an intervention has significant organisational-level impact through diversion of activity or cost (20). For detailed consideration of these issues researchers should consult current guidance on development and evaluation of complex interventions (21).

**Timing of outcome measurements**

Within each domain of outcome measure, consideration must be given to appropriate timing depending on the nature of the intervention and population (e.g. long and short term mortality, clinical complications during hospitalisation or after discharge). Timing of measurement of microbiological outcomes should be considered to assess impact on resistance including *C. difficile* and timing of process outcome measurements should be considered to assess long-term sustainability.

**Establishing superiority or non-inferiority**

Where a stewardship study sets out to establish the effectiveness of an intervention, incorporation of appropriate controls is essential if the results are to inform practice, irrespective of whether an experimental or non-experimental design is used (see below). Researchers need to decide whether their primary objective is to determine superiority or non-inferiority of the intervention *vs* control.

***Interventions aiming to improve treatment outcome***. In some situations, a relevant clinical benefit can be hypothesised for an intervention (e.g. an intervention that focuses on increasing earlier targeted treatment based on test results or preventing under-treatment) and a study assessing the effectiveness of the intervention would seek superiority of the intervention *vs.* control for an appropriate primary clinical outcome.

***Intervention aims to reduce antimicrobial exposure***. In most situations, stewardship interventions aim to preserve clinical outcome while reducing unnecessary antimicrobial exposure (e.g. less inappropriate initiation of antibiotics, choice of narrower spectrum or shorter duration) and improving quality of prescribing. As a result there is often some degree of real or perceived risk of patient-level harm, which may be specific to the intervention, patient population, setting and disease. Researchers designing effectiveness evaluations should consider what potential for patient harm would prevent adoption of the intervention ***even if it were effective in reducing antimicrobial exposure****.* Researchers should select appropriate secondary clinical endpoint(s) to address this concern. Ideally in this situation the research should seek both superiority for an appropriate process measure *and* non-inferiority (i.e. not qualitatively worse than control) for a co-primary clinical outcome. The key measure to assess non-inferiority is the non-inferiority margin, being the smallest outcome difference for which the intervention would be considered no worse than control. The size of the non-inferiority margin strongly influences the sample size required to demonstrate non-inferiority with sufficient power. What margin is chosen depends on the outcome selected. The margin needs to be small enough to exclude relevant harm, which would prevent intervention implementation into practice. Researchers should justify the non-inferiority margin chosen with regard to severity and frequency of the outcome in the control group (which may, for example be affected by case-mix (22).

Naturally, trials designed for demonstrating non-inferiority of clinical outcomes usually require large sample sizes. In such trials an interim analysis of a process outcome could be used to determine futility; if the intervention does not lead to the pursued process change continuing that intervention may not be logical, as non-inferiority will be the inevitable outcome.

Recognising that achieving adequate power to exclude clinically relevant non-inferiority will not always be feasible, the group felt that researchers should at least specify and report point estimates and confidence intervals for a single prespecified lead clinical outcome. Bayesian analyses may be helpful to directly estimate the probability that intervention is more than 2.5%, 5%, 7.5% etc inferior to control (23). Researchers should also prespecify the clinical outcomes they will use to assess the safety of the intervention, and all available clinical outcome data should be reported, in order to allow future meta-analysis. Unavailability of data should be explained. Unplanned exploratory analyses of clinical outcomes should be reported as such.

In studies addressing how interventions with established efficacy should be implemented, the quantitative outcome measures will be predominantly process measures and comparisons will seek to determine superiority of the intervention over comparator.

**Sample size calculations**

Studies evaluating effectiveness of an antimicrobial intervention need to be powered to demonstrate clinically relevant non-inferiority. In a superiority trial, detecting a large effect with high probability is almost always possible at a feasible sample size. Whereas demonstrating superiority only requires the confidence interval for the effect estimate to exclude zero, regardless of its width, determining non-inferiority requires the entire confidence interval to lie below the non-inferiority margin (24). As a result, much larger participant numbers are usually required to demonstrate non-inferiority within clinically relevant margins which may be very small and difficult to define for outcomes such as mortality (25). This difference lies in that superiority trials tend to be powered on an expected effect, which is often larger than what would be deemed a clinically relevant effect, whereas non-inferiority trials need to be powered on a clinically relevant effect.

One proposed solution to this issue is the Desirability of Outcome Ranking (DOOR)/ Response Adjusted for Days of Antibiotic Risk (RADAR) approach which uses investigator ranked composite outcomes. This approach is based on the assumption that the same outcome with less antimicrobial exposure is desirable (26). Yet, problems with clinical interpretation and sensitivity to the clinical outcomes chosen have been reported (27, 28). It remains to be determined to what extent the RADAR approach can robustly establish the effectiveness of novel stewardship interventions.

Interrupted time series studies require enough sequential measures before and after the intervention; the study’s power will depend on the number of data points, their distribution, variability, the expected strength of the intervention effect and confounding factors such as seasonality (29), and therefore there are no straightforward sample size formulae. Researchers should consider the minimal requirements set out in the Cochrane Effective Practice and Organisation of Care (EPOC) resources (30).

**Study design**

Stewardship interventions typically target prescribers/professionals rather than individual patients. As a consequence, evaluations involving individual patient randomisation are usually not possible because of contamination. Instead, intervention allocation must be clustered (e.g. hospital, ward, primary care practice, or physician). An important advantage of allocation at the cluster level is that it is more representative of real-life clinical practice. It is therefore more suited to studying both antimicrobial use interventions and antimicrobial improvement strategies rather than efficacy. Whereas in individual patient trials, randomisation can be expected to control for confounding bias and maximise internal validity, with cluster randomised controlled trials (cRCT), researchers need to give careful consideration to how clusters are defined and characterised. Clusters should be defined at the lowest level (e.g. clinical team, ward, practice, hospital) where contamination is unlikely as this will maximise the number of available clusters and hence study power. However, with the small number of clusters typically available in stewardship evaluations, randomisation cannot be relied on to avoid imbalance between intervention and control clusters. Therefore baseline imbalances which may influence the intervention’s impact (e.g. antimicrobial use, antimicrobial resistance rates, infection control standards, antimicrobial stewardship structures and processes, case-mix of patients) should be specified *a priori* and data on these should be gathered for inclusion in multivariate analyses. Baseline imbalance in factors which a strong association with outcome or that could potentially modify the effect of the intervention can be addressed through stratified randomisation (e.g. putting clusters into similar pairs and allocating one of each pair randomly to intervention vs control), or use of a cross-over design (see below). Cluster characterisation is also essential to understand any observed heterogeneity of the intervention’s effect between clusters. It optimises external validity by allowing others to judge the representativeness for their clinical practice and to understand the logistical challenges of implementation.

***Experimental study designs* (Table 3)**

Three main forms of cluster-randomised design may be appropriate depending on the intervention. As above, ***parallel cRCTs***, in which each cluster is randomised to either the intervention or control, minimise risk of contamination and maximise independence of the intervention from cluster-level characteristics. In some situations, perceptions of the intervention may influence whether clusters are willing to be randomised to control or intervention arms and hamper participation or introduce bias. ***Stepped-wedge cRCTs (swcRCTs)*** overcome this issue since all clusters receive the intervention during the trial, and allow estimation of the intervention effect within each cluster. swcRCTs can be logistically challenging to deliver since some clusters may have to wait to introduce the intervention and exposure should be avoided. Furthermore, the analysis of swcRCT is more complex (31). Randomisation of time of implementation is crucial to ensure independence of the timing of introduction from cluster-level factors. ***Cross-over cRCTs*** offer the potential to estimate intervention effects in both directions – i.e. introducing and withdrawing, but may not be practicable (e.g. it may not be feasible to withdraw an educational intervention. Alternatively, the washout phase of a cross-over study may be considered an assessment of sustainability for some forms of intervention. Assessment of carried antimicrobial resistance in crossover designs may need to consider the potential for resistance selection to persist.

A particular challenge with evaluation of interventions made at a cluster rather than patient-level is intracluster correlation (32). This must be incorporated into the sample size calculation otherwise a trial may be underpowered. Intracluster correlation is the extent to which patients are more similar to each other within a cluster than they would be if selected at random. The intracluster correlation coefficient (ICC) of an outcome is a measure of the relatedness of clustered data by comparing the variance within clusters (e.g. hospitals) with the variance between clusters. A high ICC means that observations within clusters are much more similar to each other than to observations in other clusters, while an ICC of zero means that observations within one cluster are equally similar to each other than to observations in other clusters. In general, if the ICC is large, research designs with cross-over are more efficient, while if the ICC is low, parallel cluster designs are more efficient (32).

***Quasi-experimental study designs* (Table 4)**

In situations where randomisation is not feasible or ethically not acceptable (see below), quasi-experimental, before-after-studies have the potential to deliver robust evidence of a causal relationship between an intervention and measured outcomes if they incorporate appropriate controls and analyses which account for time trends. Where control is provided through comparison with centre(s) where the intervention is not introduced, the term **Controlled Before-After (CBA)** study is used. Where control is provided by use of pre-intervention observations within centres, and secular time-trends in the outcomes are specifically accounted for, the term **Interrupted Time Series (ITS)** study is used. In practice, ITS reflects a method of analysis, being used for before and after studies and CBA, rather than a specific study type and can also be applied to CBA studies. CBA studies which do not control for time-trends are unlikely to provide reliable evidence, regardless of external control (19). The working group agreed that, design of quasi-experimental evaluations of stewardship interventions must always account for changes in time (33, 34). Such analyses require sufficient pre-intervention time points to incorporate segmented regression analysis, and should consider adjustment for autocorrelation (e.g. using ARIMA models). Such analyses should report immediate effects on outcome and trends before and after the implementation, and assess whether trends are non-linear (29, 35). Furthermore the timing of intervention implementation must be externally set to avoid the problem of regression to the mean which occurs when sites introduce a stewardship intervention in response to deterioration in the chosen outcome measure. Detailed guidance on conduct of Interrupted Time Series analyses are available through EPOC (30) and described in a recent review (36).

***Ethical considerations***

Antimicrobial stewardship measures which balance immediate and individual risks against future and societal access to effective antimicrobials raise challenging ethical issues around intergenerational justice, global distributive justice and protection of public health (37). A key ethical issue in stewardship research is that, by gathering evidence for safety through clinical outcome measures, the possibility of individual harm is acknowledged. Individual patient consent may not be feasible in studies of interventions which act on prescribers or structures such as hospitals or clinics. This may set a higher ethical barrier than for individually randomized studies in which informed consent can be obtained. In this situation the research design process should involve patients to ensure that independent non-research views from the relevant patient population about these trade-offs are heard, actively considered, and incorporated into the final design. Additionally, researchers should be able to justify why the interventions under examination are reasonable choices of practice which could also be made outside the study setting. Studies in which the intervention is made at a cluster level will often still use individual patient data. Any requirement for individual patient consent to collect data may lead to loss of representativeness and a biased assessment of the intervention effect. Because consent is acquired with knowledge of the intervention, there is an increased risk of selection bias, e.g. if investigators are more motivated to enroll patients during the intervention period. Depending on the national regulations, in some countries study designs can address this issue through use of de-identified or anonymous data (e.g. through electronic patient records) of parameters collected routinely in clinical practice without the need for individual patient consent.

**Key Design Decisions**

The consensus group considered that researchers planning antimicrobial stewardship evaluations must make a set of key decisions (Table 5) which will ultimately determine optimal study design. We have classified these decisions based on whether they apply to the ***intervention itself***, the ***evaluation setting***, the ***outcomes of interest***, the ***research objective*** and ***type of study***. Detailed explanation of the decisions are presented in **supplementary materials**.

**Discussion and conclusions**

The theoretical framework and design recommendations we present have been developed by a diverse international working group with broad and substantial expertise in antimicrobial stewardship research and practice. They address aspects of study design which are crucial to translation of research into practice and will, we believe, increase the impact of future research in this field. By drawing on wide-expertise and building our comprehensive systematic review we consider our recommendations relevant across diverse settings of care. Our work has some notable limitations. Although we gave careful consideration to the breadth of expertise required on the group and sought external advice, we did not seek lay input. We cannot discount the possibility that this would have changed our emphasis, around patient reported outcome or experience measures for example. Given the technical nature of our guidance we think it unlikely this would have changed our conclusions. An inherent risk of the consensus-group design is ’group think’ in which members trying to reach consensus fail to critically evaluate alternative views. To address this we sought critical evaluation by two highly eminent international experts in this field. Although these were also, of necessity, experts in antimicrobial stewardship research, the impact of their input on our thinking, the breadth and seniority of expertise in our group make it unlikely we have failed to consider major alternative viewpoints. Notwithstanding these caveats, we believe that application of this guidance has the potential to greatly improve the quality and impact of antimicrobial stewardship research.

**Summary Recommendations**

**Outcomes**

* Researchers should determine whether their study aims to investigate, effectiveness, or implementation (‘what or ‘how’). This will determine the priority and nature of outcomes.
* All antimicrobial stewardship studies should define process, clinical and microbiological outcomes and specify a primary process outcome(s) to measure effectiveness of the intervention.
* Unless there is pre-existing evidence that a stewardship intervention cannot or will not compromise treatment outcome, an evaluation should attempt to pre-specify a co-primary clinical/microbiological efficacy outcome on which the study is adequately powered, or, at minimum, a single lead clinical outcome.
* Clinical and microbiological data documenting treatment outcome should be collected and reported as pre-specified secondary outcomes even if the study is not powered on them
* Measurement of incidence of infections / colonisation due to multi-drug resistant bacteria and infections due to *C. difficile* infection should be included in the design of stewardship interventions whenever possible. Studies assessing resistance should clarify whether this is related to the infecting pathogen or among colonisers.

**Objectives**

* If a relevant clinical benefit can be hypothesised for an intervention, then the research objective should seek superiority for an appropriate primary clinical outcome.
* If not, researchers should seek both superiority for an appropriate process measure and ideally non-inferiority for a co-primary clinical/clinically relevant microbiological outcome.
* Researchers should justify how the non-inferiority margin has been selected and balanced against research costs and feasibility.
* Where this is not possible, as a minimum, researchers should specify, and report point estimates and confidence intervals for, at minimum, a single pre-specified lead clinical outcome.
* In situations where the study size is determined by a co-primary non-inferiority safety outcome, an interim futility analysis of the superiority process outcome should be considered to confirm a relevant change in treatment/management.

**Study design**

* Cluster randomised controlled trials (including crossover and stepped-wedge designs) are preferable to quasi-experimental before/after studies.
* The threshold for defining clusters should be as low as possible to minimise contamination, allowing the maximum number of clusters to be studied.
* In a parallel cluster RCT, randomisation should not be relied on to control for imbalance between study arms if the number of clusters is <20 per arm and stratified or matched randomisation should be considered
* Designs using within-cluster comparisons (stepped-wedge cRCT, cross-over cRCT or quasi-experimental approaches) are indicated where there are fewer than 10 clusters per arm.
* Quasi-experimental studies should incorporate appropriate controls and analyses to account for time trends
* In quasi-experimental studies, timing of the intervention should be externally set or if this is not possible timing should be explained and described.
* Segmented regression analysis of interrupted time series studies should include 12 time points with at least 100 observations per time point before and after the intervention to allow for anticipated secular trends and test or correct for autocorrelation.
* Single centre studies using a robustly designed and analysed interrupted time series approach including observations before and after the intervention should be considered the lowest quality research design which will impact on clinical practice.

**References**

1. The Review on Antimicrobial Resistance. Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations. 2014.

2. Costelloe C, Metcalfe C, Lovering A, Mant D, Hay AD. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ. 2010;340:c2096.

3. Goossens H, Ferech M, Vander Stichele R, Elseviers M, ESAC Project Group. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet. 2005;365(9459):579-87.

4. Dyar OJ, Huttner B, Schouten J, Pulcini C, Esgap. What is antimicrobial stewardship? Clin Microbiol Infect. 2017;23(11):793-8.

5. McGowan JE, Jr., Gerding DN. Does antibiotic restriction prevent resistance? New Horiz. 1996;4(3):370-6.

6. Molina J, Cisneros JM. Editorial Commentary: A Chance to Change the Paradigm of Outcome Assessment of Antimicrobial Stewardship Programs. Clin Infect Dis. 2015;61(5):807-8.

7. Schweitzer VA, van Heijl I, van Werkhoven CH, Islam J, Hendriks-Spoor KD, Bielicki J, et al. The quality of studies evaluating antimicrobial stewardship interventions: a systematic review. Clin Microbiol Infect. 2018.

8. Hulscher M, Prins JM. Antibiotic stewardship: does it work in hospital practice? A review of the evidence base. Clin Microbiol Infect. 2017;23(11):799-805.

9. Schuts EC, Hulscher M, Mouton JW, Verduin CM, Stuart J, Overdiek H, et al. Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis. Lancet Infect Dis. 2016;16(7):847-56.

10. Ramsay C, Brown E, Hartman G, Davey P. Room for improvement: a systematic review of the quality of evaluations of interventions to improve hospital antibiotic prescribing. J Antimicrob Chemother. 2003;52(5):764-71.

11. Hulscher ME, Laurant MG, Grol RP. Process evaluation on quality improvement interventions. Qual Saf Health Care. 2003;12(1):40-6.

12. Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care. 2012;50(3):217-26.

13. Burke JP. Antibiotic resistance--squeezing the balloon? JAMA. 1998;280(14):1270-1.

14. Peterson LR. Squeezing the antibiotic balloon: the impact of antimicrobial classes on emerging resistance. Clin Microbiol Infect. 2005;11 Suppl 5:4-16.

15. Toma M, Davey PG, Marwick CA, Guthrie B. A framework for ensuring a balanced accounting of the impact of antimicrobial stewardship interventions. J Antimicrob Chemother. 2017;72(12):3223-31.

16. McGregor JC, Furuno JP. Optimizing research methods used for the evaluation of antimicrobial stewardship programs. Clin Infect Dis. 2014;59 Suppl 3:S185-92.

17. Gillespie D, Francis NA, Carrol ED, Thomas-Jones E, Butler CC, Hood K. Use of co-primary outcomes for trials of antimicrobial stewardship interventions. Lancet Infect Dis. 2018;18(6):595-7.

18. Baur D, Gladstone BP, Burkert F, Carrara E, Foschi F, Dobele S, et al. Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. Lancet Infect Dis. 2017;17(9):990-1001.

19. Davey P, Marwick CA, Scott CL, Charani E, McNeil K, Brown E, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev. 2017;2:CD003543.

20. Lennox L, Maher L, Reed J. Navigating the sustainability landscape: a systematic review of sustainability approaches in healthcare. Implment. Sci. 2018;13(1):27.

21. Medical Research Council. Developing and evaluating complex interventions. 2019.

22. Piaggio G, Elbourne DR, Pocock SJ, Evans SJ, Altman DG, Group C. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA. 2012;308(24):2594-604.

23. Laptook AR, Shankaran S, Tyson JE, Munoz B, Bell EF, Goldberg RN, et al. Effect of Therapeutic Hypothermia Initiated After 6 Hours of Age on Death or Disability Among Newborns With Hypoxic-Ischemic Encephalopathy: A Randomized Clinical Trial. JAMA. 2017;318(16):1550-60.

24. Mauri L, D'Agostino RB, Sr. Challenges in the Design and Interpretation of Noninferiority Trials. N Engl J Med. 2017;377(14):1357-67.

25. Cranendonk DR, Opmeer BC, Prins JM, Wiersinga WJ. Comparing short to standard duration of antibiotic therapy for patients hospitalized with cellulitis (DANCE): study protocol for a randomized controlled trial. BMC Infect Dis. 2014;14:235.

26. Evans SR, Rubin D, Follmann D, Pennello G, Huskins WC, Powers JH, et al. Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR). Clin Infect Dis. 2015;61(5):800-6.

27. Phillips PP, Morris TP, Walker AS. DOOR/RADAR: A Gateway Into the Unknown? Clin Infect Dis. 2016;62(6):814-5.

28. Schweitzer VA, van Smeden M, Postma DF, Oosterheert JJ, Bonten MJM, van Werkhoven CH. Response Adjusted for Days of Antibiotic Risk (RADAR): evaluation of a novel method to compare strategies to optimize antibiotic use. Clin Microbiol Infect. 2017;23(12):980-5.

29. Lopez Bernal J, Soumerai S, Gasparrini A. A methodological framework for model selection in interrupted time series studies. J Clin Epidemiol. 2018;103:82-91.

30. (EPOC) CEPaOoC. What study designs can be considered for inclusion in an EPOC review and what should they be called? 2017.

31. Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, et al. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614.

32. Hemming K, Taljaard M. Sample size calculations for stepped wedge and cluster randomised trials: a unified approach. J Clin Epidemiol. 2016;69:137-46.

33. Boel J, Andreasen V, Jarlov JO, Ostergaard C, Gjorup I, Boggild N, et al. Impact of antibiotic restriction on resistance levels of Escherichia coli: a controlled interrupted time series study of a hospital-wide antibiotic stewardship programme. J Antimicrob Chemother. 2016;71(7):2047-51.

34. Taggart LR, Leung E, Muller MP, Matukas LM, Daneman N. Differential outcome of an antimicrobial stewardship audit and feedback program in two intensive care units: a controlled interrupted time series study. BMC Infect Dis. 2015;15:480.

35. Lawes T, Lopez-Lozano JM, Nebot CA, Macartney G, Subbarao-Sharma R, Wares KD, et al. Effect of a national 4C antibiotic stewardship intervention on the clinical and molecular epidemiology of Clostridium difficile infections in a region of Scotland: a non-linear time-series analysis. Lancet Infect Dis. 2017;17(2):194-206.

36. de Kraker MEA, Abbas M, Huttner B, Harbarth S. Good epidemiological practice: a narrative review of appropriate scientific methods to evaluate the impact of antimicrobial stewardship interventions. Clin Microbiol Infect. 2017;23(11):819-25.

37. Littmann J, Rid A, Buyx A. Tackling anti-microbial resistance: ethical framework for rational antibiotic use. Eur J Public Health. 2018;28(2):359-63.

38. Davey P, Peden C, Charani E, Marwick C, Michie S. Time for action-Improving the design and reporting of behaviour change interventions for antimicrobial stewardship in hospitals: Early findings from a systematic review. Int J Antimicrob Agents. 2015;45(3):203-12.

39. Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687.

40. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27(4):299-309.

41. Tacconelli E, Cataldo MA, Paul M, Leibovici L, Kluytmans J, Schroder W, et al. STROBE-AMS: recommendations to optimise reporting of epidemiological studies on antimicrobial resistance and informing improvement in antimicrobial stewardship. BMJ Open. 2016;6(2):e010134.

42. Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4(10):e297.

43. Ogrinc G, Davies L, Goodman D, Batalden P, Davidoff F, Stevens D. SQUIRE 2.0 (Standards for QUality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process. BMJ Qual Saf. 2016;25(12):986-92.

44. Des Jarlais DC, Lyles C, Crepaz N, Group T. Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: the TREND statement. Am J Public Health. 2004;94(3):361-6.

**Acknowledgements**

The authors would like Prof Dilip Nathwani and Prof Jan Prins for providing independent critical advice during the project and to Sandy Gray for administration support.

**Transparency Declaration**

The authors declare no conflicts of interest. The presented work was supported by a grant (JPIAMRWG-010) from the Joint Programming Initiative on Antimicrobial Resistance.

ASW is supported by the NIHR Oxford Biomedical Research Centre and the Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford in partnership with Public Health England (PHE) [HPRU-2012-10041], and is an NIHR Senior Investigator.

The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, the Department of Health or PHE.